Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Stopped early · Phase 1

Conditions studied: Primary Sclerosing Cholangitis, Compensated Cirrhosis

In brief

The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.

Key facts

Study ID
NCT04060147
Run by
Gilead Sciences
People needed
11
Starts
2019-10-17
Expected to finish
2021-09-02
Last updated by the study team
2023-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.